Piramal Pharma Limited Share Price & Analysis
₹160.15Updated 30 Apr 2026, 06:00 am IST
LTP
₹160.15
—
Open
₹163.25
High
₹168.67
Low
₹159.36
Close
₹160.15
52W High
₹221
52W Low
₹132
Volume
6591K
Lot Size
2625
Sector
Healthcare
Market Cap
₹22K Cr
Face Value
₹10
Large CapNIFTY 500SMALLCAP 100
Price Chart
Fundamentals
P/E
—
Sector P/E
48.9
P/B
2.61
EPS
₹-1.22
ROE
-3.58%
ROCE
2.69%
D/E Ratio
0.7
Div Yield
0.08%
Book Value
₹61.4
−
Concerns
- ✗Currently loss-making (EPS ₹-1.2)
- ✗Negative return on equity (ROE -3.6%)
- ✗Low capital efficiency (ROCE 2.7%)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,783 | ₹4.3L Cr | 34.4 | 5.12 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,616 | ₹1.7L Cr | 66.1 | 10.48 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,416 | ₹1.5L Cr | 66.4 | 17.81 | 27.6 | 15.4 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,315 | ₹1.2L Cr | 59.5 | 12.62 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,402 | ₹1.1L Cr | 27.3 | 3.29 | 12.4 | 16.6 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,091 | ₹1.1L Cr | 20 | 4.05 | 21.2 | 21.2 | 0.38 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,283 | ₹1.1L Cr | 25.4 | 2.83 | 11.8 | 13.6 | 0.16 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
PPLPHARMA · as of Mar 2026
Promoters34.94%
FII31.49%▼0.19
DII14.78%▲0.69
Public18.42%▼0.43
Others0.34%▼0.06
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 35.02% | 35.02% | 34.94% | 34.94% | 34.94% | 34.94% |
| FII | 32.51% | 30.58% | 31.41% | 31.73% | 31.68% | 31.49% |
| DII | 9.68% | 12.12% | 12.95% | 13.80% | 14.09% | 14.78% |
| Public | 22.41% | 21.89% | 20.20% | 19.06% | 18.85% | 18.42% |
| Others | 0.38% | 0.37% | 0.47% | 0.45% | 0.40% | 0.34% |
Corporate Events
To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company for quarter and financial year ended 31st March, 2026.
Results27 Apr 2026
Dividend - Re 0.14 Per Share
Dividend15 Jul 2025
Dividend - Rs 0.11 Per Share
Dividend11 Jul 2024
Rights 5:46 @ Premium Rs 71/-
Rights1 Aug 2023
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.1K Cr ▲4.7% | ₹2.0K Cr ▲5.7% | ₹1.9K Cr ▼29.8% | ₹2.8K Cr ▲24.9% | ₹2.2K Cr ▼1.7% | ₹2.2K Cr ▲14.9% | ₹2.0K Cr ▼23.5% | ₹2.6K Cr |
| Op. Profit | ₹195.73 Cr ▲23.3% | ₹158.69 Cr ▲48.7% | ₹106.7 Cr ▼81.0% | ₹560.99 Cr ▲66.1% | ₹337.74 Cr ▼1.1% | ₹341.61 Cr ▲67.1% | ₹204.49 Cr ▼61.4% | ₹530 Cr |
| OPM | 9.2% ▲17.9% | 7.8% ▲40.6% | 5.5% ▼72.9% | 20.4% ▲33.0% | 15.3% ▲0.5% | 15.2% ▲45.4% | 10.5% ▼50.1% | 21.0% |
| Net Profit | ₹-136.19 Cr ▼37.3% | ₹-99.22 Cr ▼21.4% | ₹-81.7 Cr ▼153.2% | ₹153.5 Cr ▲4071.2% | ₹3.68 Cr ▼83.7% | ₹22.59 Cr ▲125.5% | ₹-88.64 Cr ▼187.8% | ₹101 Cr |
| EPS (₹) | -1.02 ▼36.0% | -0.75 ▼23.0% | -0.61 ▼152.6% | 1.16 ▲3766.7% | 0.03 ▼82.4% | 0.17 ▲125.4% | -0.67 ▼187.0% | 0.77 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Revenue | ₹8.9K Cr ▼3.1% | ₹9.2K Cr ▲12.0% | ₹8.2K Cr ▲15.4% | ₹7.1K Cr ▲8.0% | ₹6.6K Cr ▲3.9% | ₹6.3K Cr |
| Expenses | ₹7.9K Cr ▲3.1% | ₹7.7K Cr ▲10.5% | ₹7.0K Cr ▲8.1% | ₹6.5K Cr ▲15.0% | ₹5.6K Cr ▲14.8% | ₹4.9K Cr |
| Op. Profit | ₹922 Cr ▼36.2% | ₹1.4K Cr ▲20.7% | ₹1.2K Cr ▲90.3% | ₹629 Cr ▼33.8% | ₹950 Cr ▼33.5% | ₹1.4K Cr |
| OPM | 10.0% ▼37.5% | 16.0% ▲6.7% | 15.0% ▲66.7% | 9.0% ▼35.7% | 14.0% ▼39.1% | 23.0% |
| Other Income | ₹74 Cr ▼64.4% | ₹208 Cr ▲20.9% | ₹172 Cr ▼36.8% | ₹272 Cr ▼14.7% | ₹319 Cr ▲38.7% | ₹230 Cr |
| Interest | ₹341 Cr ▼19.2% | ₹422 Cr ▼5.8% | ₹448 Cr ▲30.2% | ₹344 Cr ▲73.7% | ₹198 Cr ▲21.5% | ₹163 Cr |
| Depreciation | ₹831 Cr ▲1.8% | ₹816 Cr ▲10.1% | ₹741 Cr ▲9.5% | ₹677 Cr ▲15.5% | ₹586 Cr ▲7.5% | ₹545 Cr |
| PBT | ₹-176 Cr ▼142.4% | ₹415 Cr ▲131.8% | ₹179 Cr ▲249.2% | ₹-120 Cr ▼124.7% | ₹485 Cr ▼48.9% | ₹949 Cr |
| Tax % | 85.0% ▲9.0% | 78.0% ▼13.3% | 90.0% ▲63.6% | 55.0% ▲150.0% | 22.0% ▲83.3% | 12.0% |
| Net Profit | ₹-326 Cr ▼458.2% | ₹91 Cr ▲405.6% | ₹18 Cr ▲109.7% | ₹-186 Cr ▼149.5% | ₹376 Cr ▼55.0% | ₹835 Cr |
| EPS (₹) | -2.45 ▼455.1% | 0.69 ▲430.8% | 0.13 ▲109.2% | -1.41 | — | — |
| Div Payout | 0.0% ▼100.0% | 20.0% ▼75.6% | 82.0% | 0.0% ▼100.0% | 18.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|---|
| Liabilities | |||||||
| Equity Capital | ₹1.3K Cr ▲0.1% | ₹1.3K Cr ▲0.2% | ₹1.3K Cr ▲0.1% | ₹1.3K Cr ▲10.9% | ₹1.2K Cr ▲0.6% | ₹1.2K Cr ▲19.2% | ₹995 Cr |
| Reserves | ₹6.8K Cr ▲1.3% | ₹6.7K Cr ▼0.8% | ₹6.8K Cr ▲3.2% | ₹6.6K Cr ▲18.1% | ₹5.6K Cr ▲1.3% | ₹5.5K Cr ▲19.5% | ₹4.6K Cr |
| Borrowings | ₹5.7K Cr ▲17.0% | ₹4.9K Cr ▼0.1% | ₹4.9K Cr ▲3.1% | ₹4.7K Cr ▼16.4% | ₹5.6K Cr ▲36.6% | ₹4.1K Cr ▲36.5% | ₹3.0K Cr |
| Other Liabilities | ₹4.1K Cr ▲26.4% | ₹3.3K Cr ▲33.4% | ₹2.4K Cr ▼0.6% | ₹2.5K Cr ▲30.0% | ₹1.9K Cr ▲6.3% | ₹1.8K Cr ▼13.0% | ₹2.0K Cr |
| Total Liabilities | ₹18.0K Cr ▲11.0% | ₹16.2K Cr ▲4.9% | ₹15.4K Cr ▲2.3% | ₹15.1K Cr ▲5.5% | ₹14.3K Cr ▲13.5% | ₹12.6K Cr ▲18.1% | ₹10.7K Cr |
| Assets | |||||||
| Fixed Assets | ₹9.0K Cr ▲1.8% | ₹8.8K Cr ▲8.5% | ₹8.1K Cr ▲1.8% | ₹8.0K Cr ▲7.0% | ₹7.5K Cr ▲8.6% | ₹6.9K Cr ▲12.7% | ₹6.1K Cr |
| CWIP | ₹799 Cr ▲40.9% | ₹567 Cr ▼42.0% | ₹977 Cr ▼12.5% | ₹1.1K Cr ▼21.4% | ₹1.4K Cr ▲21.1% | ₹1.2K Cr ▲86.9% | ₹627 Cr |
| Investments | ₹437 Cr ▼1.1% | ₹442 Cr ▲51.9% | ₹291 Cr ▼24.4% | ₹385 Cr ▼39.7% | ₹639 Cr ▲139.3% | ₹267 Cr ▲117.1% | ₹123 Cr |
| Other Assets | ₹7.7K Cr ▲21.9% | ₹6.4K Cr ▲5.4% | ₹6.0K Cr ▲7.8% | ₹5.6K Cr ▲17.1% | ₹4.8K Cr ▲11.5% | ₹4.3K Cr ▲12.1% | ₹3.8K Cr |
| Total Assets | ₹18.0K Cr ▲11.0% | ₹16.2K Cr ▲4.9% | ₹15.4K Cr ▲2.3% | ₹15.1K Cr ▲5.5% | ₹14.3K Cr ▲13.5% | ₹12.6K Cr ▲18.1% | ₹10.7K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Operating CF | ₹1.7K Cr ▲85.3% | ₹892 Cr ▼11.2% | ₹1.0K Cr ▲107.6% | ₹484 Cr ▼36.8% | ₹766 Cr ▲28.1% | ₹598 Cr |
| Investing CF | ₹-826 Cr ▼69.3% | ₹-488 Cr ▼17.3% | ₹-416 Cr ▲68.8% | ₹-1.3K Cr ▲23.2% | ₹-1.7K Cr ▲61.1% | ₹-4.5K Cr |
| Financing CF | ₹-39 Cr ▲91.2% | ₹-441 Cr ▼4.5% | ₹-422 Cr ▼151.6% | ₹818 Cr ▲3.0% | ₹794 Cr ▼80.0% | ₹4.0K Cr |
| Net Cash Flow | ₹788 Cr ▲2229.7% | ₹-37 Cr ▼122.3% | ₹166 Cr ▲618.8% | ₹-32 Cr ▲81.9% | ₹-177 Cr ▼260.9% | ₹110 Cr |
| Free Cash Flow | ₹776 Cr ▲233.0% | ₹233 Cr ▼20.7% | ₹294 Cr ▲163.8% | ₹-461 Cr ▼406.6% | ₹-91 Cr ▼1720.0% | ₹-5 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Debtor Days | 89d ▼5.3% | 94d ▼1.1% | 95d ▲2.2% | 93d ▼6.1% | 99d ▲8.8% | 91d |
| Inventory Days | 345d ▲32.2% | 261d ▼3.0% | 269d ▲18.5% | 227d ▲9.7% | 207d ▼5.0% | 218d |
| Days Payable | 279d ▲61.3% | 173d ▼8.9% | 190d ▲18.0% | 161d ▲5.2% | 153d ▼6.1% | 163d |
| Cash Conv. Cycle | 155d ▼14.8% | 182d ▲4.6% | 174d ▲9.4% | 159d ▲3.9% | 153d ▲4.1% | 147d |
| Working Capital Days | 50d ▼16.7% | 60d ▲185.7% | 21d ▲61.5% | 13d ▼63.9% | 36d ▼18.2% | 44d |
| ROCE | 3.0% ▼50.0% | 6.0% ▲20.0% | 5.0% ▲150.0% | 2.0% ▼71.4% | 7.0% | — |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Piramal Pharma Limited
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments (1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions[1] and various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billion[2] and Diagnostic Services was sold to Super Religare Laboratories (SRL)[3]
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Piramal Pharma Limited share price today?▾
Piramal Pharma Limited (PPLPHARMA) is currently trading at ₹160.15 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Piramal Pharma Limited available in F&O (Futures & Options)?▾
Yes, Piramal Pharma Limited (PPLPHARMA) is part of the NSE F&O segment with a lot size of 2625 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Piramal Pharma Limited 52-week high and low?▾
Piramal Pharma Limited's 52-week high is ₹221 and the 52-week low is ₹132. The current price of ₹160.15 is 27.5% below the 52W high.
What is Piramal Pharma Limited P/E ratio?▾
Piramal Pharma Limited's P/E ratio and other fundamental metrics including P/B, ROE, and ROCE are available on the overview page. Data is sourced weekly from Screener.in.
How to trade Piramal Pharma Limited options?▾
Piramal Pharma Limited options are traded on NSE with monthly expiry contracts (lot size: 2625 shares). To trade PPLPHARMA options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.